SuperworthAcurx Pharmaceuticals EPS ACXP
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$3.11
- Latest quarter, Q2 FY26
- −$0.53
- Fiscal year 2025
- −$6.00
Acurx Pharmaceuticals' earnings per share was −$3.11 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.53.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$6.00 | n/a |
| FY2024 | −$17.55 | n/a |
| FY2023 | −$22.80 | n/a |
| FY2022 | −$22.40 | n/a |
| FY2021 | −$30.00 | n/a |
| FY2020 | −$14.80 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.53 | n/a | −$3.11 | |
| Q1 FY26 | −$0.62 | n/a | −$4.47 | |
| Q4 FY25 | −$0.73 | n/a | −$6.00 | |
| Q3 FY25 | −$1.23 | n/a | −$8.56 | |
| Q2 FY25 | −$1.89 | n/a | −$10.78 | |
| Q1 FY25 | −$2.15 | n/a | −$14.10 | |
| Q4 FY24 | −$3.29 | n/a | −$17.55 | |
| Q3 FY24 | −$3.45 | n/a | −$21.66 | |
| Q2 FY24 | −$5.21 | n/a | −$23.01 | |
| Q1 FY24 | −$5.60 | n/a | −$23.40 | |
| Q4 FY23 | −$7.40 | n/a | −$22.80 | |
| Q3 FY23 | −$4.80 | n/a | −$21.00 |
Against its peers
Companies in Healthcare nearest Acurx Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ACXPAcurx Pharmaceuticals | −$3.11 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Acurx Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.